DK166429B1 - Anvendelse af kojisyre eller kojisyre/beta-cyclodextrinindlejringskompleks til fremstilling af laegemidler til forebyggelse af elastosis - Google Patents
Anvendelse af kojisyre eller kojisyre/beta-cyclodextrinindlejringskompleks til fremstilling af laegemidler til forebyggelse af elastosis Download PDFInfo
- Publication number
- DK166429B1 DK166429B1 DK313786A DK313786A DK166429B1 DK 166429 B1 DK166429 B1 DK 166429B1 DK 313786 A DK313786 A DK 313786A DK 313786 A DK313786 A DK 313786A DK 166429 B1 DK166429 B1 DK 166429B1
- Authority
- DK
- Denmark
- Prior art keywords
- acid
- elastosis
- cyclodextrin
- kojic acid
- cojic acid
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 title abstract description 12
- 239000001116 FEMA 4028 Substances 0.000 title abstract description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title abstract description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 title abstract description 9
- 229960004853 betadex Drugs 0.000 title abstract description 9
- 239000002253 acid Substances 0.000 title description 13
- 230000006378 damage Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 title description 2
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004705 kojic acid Drugs 0.000 claims abstract description 17
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 6
- 239000000839 emulsion Substances 0.000 claims abstract description 6
- 239000006071 cream Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000002674 ointment Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 9
- 241000700159 Rattus Species 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000005562 fading Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000003906 humectant Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- -1 Polyoxyethylene stearyl ether Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000002316 solid fats Nutrition 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019809 paraffin wax Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Electroluminescent Light Sources (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60146029A JPH0613448B2 (ja) | 1985-07-02 | 1985-07-02 | 皮膚弾力線維症予防剤 |
| JP14602985 | 1985-07-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK313786D0 DK313786D0 (da) | 1986-07-01 |
| DK313786A DK313786A (da) | 1987-01-03 |
| DK166429B1 true DK166429B1 (da) | 1993-05-24 |
Family
ID=15398494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK313786A DK166429B1 (da) | 1985-07-02 | 1986-07-01 | Anvendelse af kojisyre eller kojisyre/beta-cyclodextrinindlejringskompleks til fremstilling af laegemidler til forebyggelse af elastosis |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4891361A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0207499B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH0613448B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR890004556B1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE75396T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU591680B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1282332C (cg-RX-API-DMAC7.html) |
| DE (1) | DE3685060D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK166429B1 (cg-RX-API-DMAC7.html) |
| FI (1) | FI862806A0 (cg-RX-API-DMAC7.html) |
| GR (1) | GR861671B (cg-RX-API-DMAC7.html) |
| HK (1) | HK51594A (cg-RX-API-DMAC7.html) |
| IE (1) | IE59082B1 (cg-RX-API-DMAC7.html) |
| IN (1) | IN165985B (cg-RX-API-DMAC7.html) |
| PH (1) | PH22349A (cg-RX-API-DMAC7.html) |
| PT (1) | PT82889B (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA864166B (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2809429B2 (ja) * | 1989-05-26 | 1998-10-08 | 湧永製薬株式会社 | 制ガン剤ならびに制ガン剤として有用な新規複素環化合物またはそれらの塩 |
| JPH04298437A (ja) * | 1991-03-26 | 1992-10-22 | Fuji Photo Film Co Ltd | 画像形成装置 |
| US5296472A (en) * | 1991-12-05 | 1994-03-22 | Vyrex Corporation | Methods for delipidation of skin and cerumen removal |
| JP3566739B2 (ja) * | 1993-09-30 | 2004-09-15 | 三省製薬株式会社 | 皮膚外用剤の安定化方法 |
| US5874463A (en) | 1994-10-24 | 1999-02-23 | Ancira; Margaret | Hydroxy-kojic acid skin peel |
| US6596263B1 (en) * | 1995-07-14 | 2003-07-22 | Stc English Ideas, Inc. | Cyclodextrin compositions |
| GB2307176A (en) * | 1995-11-15 | 1997-05-21 | Todd Selwyn Everest | Anti-inflammatory clathrating agents for topical use |
| KR100471372B1 (ko) * | 2001-12-04 | 2005-03-08 | 주식회사 태평양 | 피부 탄력 향상용 화장료 조성물 |
| US20040126339A1 (en) * | 2002-12-31 | 2004-07-01 | Roszell James A. | Sunscreen composition and methods for manufacturing and using a sunscreen composition |
| US20080070982A1 (en) * | 2006-09-15 | 2008-03-20 | Graham Timmins | System and methods of melanoma prevention |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS533538A (en) * | 1976-06-28 | 1978-01-13 | Sansho Seiyaku Kk | Skin bleach cosmetics |
| JPS55157509A (en) * | 1979-05-24 | 1980-12-08 | Sansho Seiyaku Kk | Ultraviolet ray intercepting agent safe to skin |
| JPS61109705A (ja) * | 1984-11-01 | 1986-05-28 | Sansho Seiyaku Kk | 色白化粧料 |
-
1985
- 1985-07-02 JP JP60146029A patent/JPH0613448B2/ja not_active Expired - Lifetime
-
1986
- 1986-06-04 ZA ZA864166A patent/ZA864166B/xx unknown
- 1986-06-04 KR KR1019860004420A patent/KR890004556B1/ko not_active Expired
- 1986-06-04 IE IE148186A patent/IE59082B1/en not_active IP Right Cessation
- 1986-06-05 CA CA000510952A patent/CA1282332C/en not_active Expired - Lifetime
- 1986-06-12 IN IN440/CAL/86A patent/IN165985B/en unknown
- 1986-06-16 AU AU58897/86A patent/AU591680B2/en not_active Expired
- 1986-06-25 PH PH33945A patent/PH22349A/en unknown
- 1986-06-26 GR GR861671A patent/GR861671B/el unknown
- 1986-07-01 AT AT86108952T patent/ATE75396T1/de active
- 1986-07-01 FI FI862806A patent/FI862806A0/fi not_active Application Discontinuation
- 1986-07-01 EP EP86108952A patent/EP0207499B1/en not_active Expired - Lifetime
- 1986-07-01 PT PT82889A patent/PT82889B/pt not_active IP Right Cessation
- 1986-07-01 DK DK313786A patent/DK166429B1/da not_active IP Right Cessation
- 1986-07-01 DE DE8686108952T patent/DE3685060D1/de not_active Expired - Lifetime
-
1988
- 1988-05-18 US US07/198,637 patent/US4891361A/en not_active Expired - Lifetime
-
1994
- 1994-05-19 HK HK51594A patent/HK51594A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU591680B2 (en) | 1989-12-14 |
| FI862806A0 (fi) | 1986-07-01 |
| HK51594A (en) | 1994-05-27 |
| DK313786D0 (da) | 1986-07-01 |
| PT82889A (en) | 1986-08-01 |
| DK313786A (da) | 1987-01-03 |
| GR861671B (en) | 1986-10-30 |
| EP0207499A2 (en) | 1987-01-07 |
| JPH0613448B2 (ja) | 1994-02-23 |
| ZA864166B (en) | 1987-02-25 |
| DE3685060D1 (de) | 1992-06-04 |
| IE59082B1 (en) | 1994-01-12 |
| US4891361A (en) | 1990-01-02 |
| PT82889B (pt) | 1988-05-27 |
| KR870000931A (ko) | 1987-03-10 |
| EP0207499B1 (en) | 1992-04-29 |
| IE861481L (en) | 1987-01-02 |
| IN165985B (cg-RX-API-DMAC7.html) | 1990-02-17 |
| CA1282332C (en) | 1991-04-02 |
| JPS625909A (ja) | 1987-01-12 |
| AU5889786A (en) | 1987-01-08 |
| ATE75396T1 (de) | 1992-05-15 |
| KR890004556B1 (ko) | 1989-11-15 |
| EP0207499A3 (en) | 1989-04-26 |
| PH22349A (en) | 1988-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA015246B1 (ru) | Неводная композиция стабильной аскорбиновой кислоты и способ ее приготовления | |
| JPH09143063A (ja) | 外用に適する組成物 | |
| DK166429B1 (da) | Anvendelse af kojisyre eller kojisyre/beta-cyclodextrinindlejringskompleks til fremstilling af laegemidler til forebyggelse af elastosis | |
| US20120065159A1 (en) | Composition containing chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
| JPWO2000009121A1 (ja) | 消炎鎮痛剤 | |
| DK165903B (da) | Farmaceutisk praeparat mod acne | |
| JPH027287B2 (cg-RX-API-DMAC7.html) | ||
| JP2001097888A (ja) | 外用組成物 | |
| JP3881411B2 (ja) | 外用に適する組成物 | |
| JP2006348035A (ja) | 外用に適する組成物 | |
| JPH0632728A (ja) | 皮膚外用剤 | |
| JP2001114636A (ja) | ヒアルロン酸産生及びカタラーゼ産生促進剤、線維芽細胞賦活剤、並びに皮膚外用剤 | |
| DE60035613T2 (de) | Topische,kosmetische und pharmazeutische Mittel,enthaltend spezifische alkoxylierte Diester der Fumarsäure | |
| JPH0532556A (ja) | 皮膚外用剤 | |
| HU211100B (en) | Cosmetic composition with skin regenerating effect, comprising active ingredients of vegetable origin | |
| JPS6360910A (ja) | 皮膚外用剤 | |
| JP3522609B2 (ja) | ヒアルロン酸産生促進剤、及びこれを含有して成る皮膚外用剤 | |
| JP2008088075A (ja) | プロフィラグリン／フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮／角層正常化用皮膚外用剤、プロフィラグリン及び／又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
| JP7634814B2 (ja) | 被膜形成能を有する高分子量セリシン組成物およびその製造方法 | |
| US4272516A (en) | Process for improving transcutaneous and transfollicular absorption of cosmetic compositions | |
| JPH03200708A (ja) | 皮膚外用剤 | |
| JP2010047535A (ja) | 皮膚外用剤 | |
| JP2000143527A (ja) | ヒアルロン酸産生促進剤、及びこれを含有して成る皮膚外用剤 | |
| KR20170130159A (ko) | 수용성 프로폴리스를 함유하는 여드름의 예방 또는 치료용 조성물 | |
| JP2000178118A (ja) | 保湿剤及び皮膚化粧料並びに入浴剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |